Loss of p53 function in certain tumor types is associated with chemoresistance, and cancers with p53 mutations are generally poorly responsive to therapeutic agents, thus necessitating the search for anticancer agents that act independently of p53 status [114]. The gene discussed is TP53; the disease is cancer.